Capstone Investment Advisors LLC bought a new position in shares of ABIVAX Société Anonyme (NASDAQ:ABVX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 57,767 shares of the company's stock, valued at approximately $618,000. Capstone Investment Advisors LLC owned approximately 0.09% of ABIVAX Société Anonyme as of its most recent SEC filing.
Separately, Franklin Resources Inc. purchased a new position in ABIVAX Société Anonyme in the fourth quarter worth $13,630,000. 47.91% of the stock is currently owned by hedge funds and other institutional investors.
ABIVAX Société Anonyme Trading Up 4.9 %
ABVX stock traded up $0.66 during trading on Friday, hitting $14.00. 21,049 shares of the company traded hands, compared to its average volume of 92,400. The company has a 50-day moving average of $14.60 and a 200-day moving average of $12.83. ABIVAX Société Anonyme has a 1 year low of $7.99 and a 1 year high of $17.02.
Wall Street Analyst Weigh In
A number of equities research analysts have weighed in on the company. Piper Sandler started coverage on ABIVAX Société Anonyme in a research report on Monday, April 29th. They set an "overweight" rating and a $42.00 price target on the stock. Guggenheim assumed coverage on ABIVAX Société Anonyme in a research report on Monday, April 29th. They issued a "buy" rating and a $50.00 target price for the company. BTIG Research began coverage on shares of ABIVAX Société Anonyme in a research report on Monday, May 20th. They set a "buy" rating and a $43.00 price target on the stock. Finally, Morgan Stanley boosted their price objective on shares of ABIVAX Société Anonyme from $15.00 to $16.00 and gave the stock an "equal weight" rating in a report on Thursday, April 11th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $34.20.
View Our Latest Stock Report on ABIVAX Société Anonyme
About ABIVAX Société Anonyme
(
Free Report)
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
Read More
Before you consider ABIVAX Société Anonyme, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ABIVAX Société Anonyme wasn't on the list.
While ABIVAX Société Anonyme currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
